Middle East and Africa Mycoplasma Testing in Clinical Market, By Products (Kits and Reagents, Instruments, Services), Technique (Microbial Culture Techniques/Direct Assay, Polymerase Chain Reaction, ELISA, DNA Staining/Indirect Assay, Enzymatic Methods), Disease Area (Respiratory, Urogenital, Gastrointestinal, Musculoskeletal, Cardiovascular, Others), End User (Diagnostic Laboratories, Hospitals) – Industry Trends and Forecast to 2030.
Middle East and Africa Mycoplasma Testing In Clinical Market Analysis and Size
As per the CDC, the number of deaths from chronic lower respiratory diseases will be 152,657 in 2021. The number of deaths from pulmonary disease, respiratory illnesses, and tuberculosis has increased, and these figures are anticipated to rise further in the upcoming years, boosting the growth of the mycoplasma testing in clinical market. Additionally, major market players expect an increase in demand for improved diagnostics for non-pulmonary therapies, which will enhance the global market in the near future.
Data Bridge Market Research analyses a growth rate in the mycoplasma testing in clinical market in the forecast period 2023-2030. The expected CAGR of mycoplasma testing in clinical market is tend to be around 5.10% in the mentioned forecast period. The market is valued at USD 11.01 million in 2022, and it would grow upto USD 16.39 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Middle East and Africa Mycoplasma Testing In Clinical Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Products (Kits and Reagents, Instruments, Services), Technique (Microbial Culture Techniques/Direct Assay, Polymerase Chain Reaction, ELISA, DNA Staining/Indirect Assay, Enzymatic Methods), Disease Area (Respiratory, Urogenital, Gastrointestinal, Musculoskeletal, Cardiovascular, Others), End User (Diagnostic Laboratories, Hospitals
|
|
Countries Covered
|
Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)
|
|
Market Players Covered
|
AB ANALITICA s.r.l. (Italy), BIOMÉRIEUX (France), ELITechGroup (France), Liofilchem S.r.l. (Italy), Agilent Technologies, Inc. (U.S.), PromoCell GmbH (Germany), F. Hoffmann-La Roche Ltd (Switzerland), OSANG Healthcare (South Korea), Sacace Biotechnologies Srl (Italy), Lonza (Switzerland), Merck KGaA (Germany), Seegene Inc. (South Korea), Clongen Laboratories, LLC (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Charles River Laboratories (U.S.), Bionique Testing Laboratories LLC (U.S.) and ZEAKON Diagnostics (India)
|
|
Market Opportunities
|
|
Market Definition
Mycoplasma testing is widely used to identify an active or recent mycoplasma infection, which is a kind of bacterial infection. Testing may be done in a number of ways depending on which one is suspected, as there are different types of mycoplasma infections such as Mycoplasma pneumoniae, which causes upper respiratory infections and can be further tested with a blood sample. Other mycoplasma tests, may demand the collection of numerous types of samples, such as joint fluid, sputum, body fluids, tissue samples, or a genital swab.
Middle East and Africa Mycoplasma Testing In Clinical Dynamics
Drivers
- Growing R&D Investments
Increasing research costs and R&D investments by major market players will likely influence firms to adopt highly efficient mycoplasma testing tools. For instance, Bristol-Myers Squibb started investing in investigational medicines to support clinical trials. Additionally, with the launch of biosimilar and the resulting lucrative R&D investment, it has become critical to perform safety testing to assure that a product meets safety, efficacy, and overall public health standards. Merck KGaA extended its manufacturing footprint in the U.S. in December 2020, investing more than USD 45.6 million in its Massachusetts and New Hampshire production facilities. The sites were designed to produce a number of biopharmaceutical manufacturing products. Therefore, this factor increases the growth of the market.
- Development of Newer Technologies
The increasing adoption of new technologies for drug research and development and advancements in cell culture technology drives the increasing need for mycoplasma tests. For instance, bioMérieux SA launched a molecular biology test known as BIOFIRE MYCOPLASMA test in July 2020, for the detection of mycoplasma in biotherapeutics. This is an innovative and easy-to-use test that can increase and simplify mycoplasma detection in biopharmaceutical products. This factor improves the market growth.
Opportunities
- Higher Demand of Kits and Reagents
The market seems to rise due to the increased demand for mycoplasma detection products and their high cost. Numerous market players have developed mycoplasma detection kits particularly to the needs of researchers and biologic manufacturers, which is boosting segment growth. Instruments are expected to experience major growth during the forecast period because of the increasing availability of automated equipment for the detection of mycoplasma. Thus, this factor created much opportunity for the market growth.
- Increase in Mycoplasma Contamination
A rise in mycoplasma contamination in cell culture is estimated to increase the growth of the market during the forecast period. Toxin development and changes in metabolite production in cell culture can be caused by mycoplasma contamination. Consequently, cell line testing and authentication are given the highest importance in the biopharmaceutical and pharmaceutical industries. Thus, this factor increases the growth of the market.
Restraints/Challenges
- Inadequate Reimbursement Policies
Even though several testing products were launched, but not all the products were launched at a cheap price. An inadequate reimbursement scenario is estimated to restrict the use of mycoplasma testing and reduce the growth of the market during the forecast period 2023-2030. Thus, this hampers the market growth.
This mycoplasma testing in clinical market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the mycoplasma testing in clinical market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Middle East and Africa Medical Mycoplasma Testing In Clinical Market Scope
The mycoplasma testing in clinical market is segmented on the basis of products, technique, disease area and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Products
- Kits and Reagents
- Instruments
- Services
Technique
- Microbial Culture Techniques/Direct Assay
- Polymerase Chain Reaction
- ELISA
- DNA Staining/Indirect Assay
- Enzymatic Methods
Disease Area
- Respiratory
- Urogenital
- Gastrointestinal
- Musculoskeletal
- Cardiovascular
- Others
End-User
- Diagnostic Laboratories
- Hospitals
Mycoplasma Testing In Clinical Market Regional Analysis/Insights
The mycoplasma testing in clinical market is analyzed and market size insights and trends are provided by products, technique, disease area and end user as referenced above.
The major countries covered in the mycoplasma testing in clinical market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
Saudi Arabia is anticipated to grow with the highest CAGR in the forecast period because of the rise in incidence of mycoplasma infection in among children. Also, the increased demand for effective testing, the increased launches of kits and reagents increase the demand of the market in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Mycoplasma Testing In Clinical Market Share Analysis
The mycoplasma testing in clinical market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to mycoplasma testing in clinical market
Key players operating in the mycoplasma testing in clinical market include:
- AB ANALITICA s.r.l. (Italy)
- BIOMÉRIEUX (France)
- ELITechGroup (France)
- Liofilchem S.r.l. (Italy)
- Agilent Technologies, Inc. (U.S.)
- PromoCell GmbH (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- OSANG Healthcare (South Korea)
- Sacace Biotechnologies Srl (Italy)
- Lonza (Switzerland)
- Merck KGaA (Germany)
- Seegene Inc. (South Korea)
- Clongen Laboratories, LLC (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Charles River Laboratories (U.S.)
- Bionique Testing Laboratories LLC (U.S.)
- ZEAKON Diagnostics (India)
SKU-